2. NF-κB Apoptosis MAPK/ERK Pathway Metabolic Enzyme/Protease Immunology/Inflammation Cell Cycle/DNA Damage Epigenetics
  3. NF-κB Apoptosis p38 MAPK Ferroptosis Cytochrome P450 Reactive Oxygen Species (ROS) SOD Lactate Dehydrogenase PERK MEK Bcl-2 Family NO Synthase COX PARP
  4. Rehmannioside A

Rehmannioside A is a compound that can be isolated from Rehmanniae radix. Rehmannioside A is an inhibitor of CYP3A4, 2C9 and 2D6, with IC50 values of 10.08, 12.62 and 16.43 μM, respectively. Rehmannioside A has anti-inflammatory, antioxidant, anti-apoptosis, anti-ferroptosis, cognitive improvement and neuroprotective activities. Rehmannioside A can be used for the research of nervous system and inflammation-related diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Rehmannioside A

Rehmannioside A 構造式

CAS 番号 : 81720-05-0

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 208 在庫あり
Solution
10 mM * 1 mL in DMSO USD 208 在庫あり
Solid
5 mg $180 在庫あり
10 mg $270 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Rehmannioside A 関連抗体

Top Publications Citing Use of Products

NF-κB アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

p38 MAPK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

Cytochrome P450 アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A CYP3A4 CYP17A1

MEK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
MEK1 MEK2 MEK5 MEK MAP2K4/MEK4 MAP2K7/MEK7

Bcl-2 Family アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

NO Synthase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
nNOS iNOS eNOS

COX アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
COX COX-1 COX-2 COX-3

PARP アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示
PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Rehmannioside A is a compound that can be isolated from Rehmanniae radix. Rehmannioside A is an inhibitor of CYP3A4, 2C9 and 2D6, with IC50 values of 10.08, 12.62 and 16.43 μM, respectively. Rehmannioside A has anti-inflammatory, antioxidant, anti-apoptosis, anti-ferroptosis, cognitive improvement and neuroprotective activities. Rehmannioside A can be used for the research of nervous system and inflammation-related diseases[1][2][3][4].

IC50 & Target[1][2][3]

CYP2C9

12.62 μM (IC50)

CYP3A4

10.08 μM (IC50)

CYP2D6

16.43 μM (IC50)

iNOS

 

Bcl-2

 

COX-2

 

Cellular Effect
Cell Line Type Value Description References
A2780 IC50
> 10 μM
Compound: 16
Cytotoxicity against human A2780 cells by MTT assay
Cytotoxicity against human A2780 cells by MTT assay
[PMID: 26859776]
A549 IC50
> 10 μM
Compound: 16
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
[PMID: 26859776]
BGC-823 IC50
> 10 μM
Compound: 16
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
[PMID: 26859776]
Bel-7402 IC50
> 10 μM
Compound: 16
Cytotoxicity against human Bel7402 cells by MTT assay
Cytotoxicity against human Bel7402 cells by MTT assay
[PMID: 26859776]
HT-29 IC50
> 10 μM
Compound: 16
Cytotoxicity against human HT-29 cells by MTT assay
Cytotoxicity against human HT-29 cells by MTT assay
[PMID: 26859776]
体外実験

Rehmannioside A (0-100 μM; 24 h) can improve high-glucose-induced decrease in cell viability and inhibit apoptosis and oxidative stress in HK2 cells (increasing the activities of SOD and CAT, reducing the levels of MDA, and decreasing LDH release and ROS production). The mechanism is involved in the inhibition of p38 MAPK and ERK1/2 phosphorylation[1].
Rehmannioside A (0-80 μM; 48 h) inhibits the release of pro-inflammatory mediators and promotes M2 polarization in LPS (HY-D1056)-treated BV2 cells. The mechanism is related to the inhibition of NF-κB and MEK signaling pathways[2].
Rehmannioside A (80 μM; 48 h) reduces neuronal apoptosis and restores the expression of anti-apoptotic protein Bcl-2 in the co-culture system of PC12 and BV2 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rehmannioside A 関連抗体

Western Blot Analysis[1]

Cell Line: HK2 cells treated high-glucose
Concentration: 20, 40 and 80 μM
Incubation Time: 24 h
Result: Significantly inhibited the levels of BAX and cleaved PARP proteins and increased Bcl-2 levels.

Western Blot Analysis[2]

Cell Line: BV2 cells treated LPS (HY-D1056)
Concentration: 0, 20, 40 and 80 μM
Incubation Time: Pretreated with 24 h, then co-incubation for 24 h
Result: Inhibited the levels of iNOS and COX-2.
体内実験

Rehmannioside A (80 mg/kg; intraperitoneal injection; 28 days) exerts a beneficial effect in a rat model of spinal cord injury[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female SD rats (200-250 g) with spinal cord injury[2]
Dosage: 80 mg/kg
Administration: Intraperitoneal injection; 28 days
Result: Significantly improved the behavioural and histological indices.
Promoted M2 microglial polarization.
Alleviated neuronal apoptosis.
Increased motor function recovery.
分子量

524.47

分子式

C21H32O15
CAS 番号
Appearance

Solid

Color

White to off-white

SMILES

OC[C@@]1([C@]([C@@H]2O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]([C@H]3O)CO[C@H]([C@@H]([C@H]4O)O)O[C@@H]([C@@H]4O)CO)([H])[C@](C=CO2)([H])[C@@H]5O)[C@@]5([H])O1
Structure Classification
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度
体外: 

H2O : ≥ 100 mg/mL (190.67 mM)

DMSO : 50 mg/mL (95.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9067 mL 9.5334 mL 19.0669 mL
5 mM 0.3813 mL 1.9067 mL 3.8134 mL
10 mM 0.1907 mL 0.9533 mL 1.9067 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始）

C1

×
体積 （開始）

V1

=
濃度 （終了）

C2

×
体積 （終了）

V2

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1.25 mg/mL (2.38 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 1.25 mg/mL (2.38 mM); Clear solution

    This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
純度とドキュメンテーション

純度: 99.96%

COA (257 KB) HNMR (281 KB) RP-HPLC (201 KB) MS (80 KB)

取扱説明書 (2659 KB)
参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / H2O 1 mM 1.9067 mL 9.5334 mL 19.0669 mL 47.6672 mL
5 mM 0.3813 mL 1.9067 mL 3.8134 mL 9.5334 mL
10 mM 0.1907 mL 0.9533 mL 1.9067 mL 4.7667 mL
15 mM 0.1271 mL 0.6356 mL 1.2711 mL 3.1778 mL
20 mM 0.0953 mL 0.4767 mL 0.9533 mL 2.3834 mL
25 mM 0.0763 mL 0.3813 mL 0.7627 mL 1.9067 mL
30 mM 0.0636 mL 0.3178 mL 0.6356 mL 1.5889 mL
40 mM 0.0477 mL 0.2383 mL 0.4767 mL 1.1917 mL
50 mM 0.0381 mL 0.1907 mL 0.3813 mL 0.9533 mL
60 mM 0.0318 mL 0.1589 mL 0.3178 mL 0.7945 mL
80 mM 0.0238 mL 0.1192 mL 0.2383 mL 0.5958 mL
H2O 100 mM 0.0191 mL 0.0953 mL 0.1907 mL 0.4767 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Rehmannioside A Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます：C1V1 = C2V2

濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rehmannioside A81720-05-0NF-κBApoptosisp38 MAPKFerroptosisCytochrome P450Reactive Oxygen Species (ROS)SODLactate DehydrogenasePERKMEKBcl-2 FamilyNO SynthaseCOXPARPNuclear factor-κBNuclear factor-kappaBCYPsSuperoxide DismutaseLDHProtein kinase R-like endoplasmic reticulum kinasePKR-like endoplasmic reticulum kinaseMitogen-activated protein kinase kinaseMAPKKMAP2KNitric oxide synthasesNOSCyclooxygenasepoly ADP ribose polymerasespinal cord injuryneuroprotectionHK2 cellsBV2 cellsPC12 cellsInhibitorinhibitorinhibit

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

  

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

      

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Rehmannioside A
製品番号:
HY-N0911
数量:
MCE 日本正規代理店:

カスタマーレビュー

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

製品名

  

Lot #

お名前 *

 

メールアドレス *

電話番号 *

 

部門 *

組纖名 *

 

国或いは地域 *

備考

Request for HNMR Report

We have received your request and will respond to you as soon as possible.